Aprea Therapeutics, Inc. Accumulated Other Comprehensive Income
Aprea Therapeutics, Inc. (APRE) had Accumulated Other Comprehensive Income of -$10.62 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-12
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$10.62M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$10.63M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$10.63M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$10.63M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$10.62M 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$10.63M 10-Q · filed 2026-05-13 |
| 2025-12-31 | -$10.63M 10-Q · filed 2026-08-12 |
| 2025-09-30 | -$10.63M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$10.63M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$10.63M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$10.63M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$10.60M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$10.63M 10-Q · filed 2024-08-12 |
| 2024-03-31 | -$10.63M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$10.61M 10-K · filed 2025-03-25 |
| 2023-09-30 | -$10.64M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$10.63M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$10.56M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$10.62M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$10.24M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$10.27M 10-Q · filed 2022-08-12 |
| 2022-03-31 | -$10.42M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$10.36M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$10.45M 10-Q · filed 2021-11-08 |
| 2021-06-30 | -$10.25M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$10.44M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$10.04M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$12.37M 10-Q · filed 2020-11-06 |
| 2020-06-30 | -$12.20M 10-Q · filed 2020-08-11 |
| 2020-03-31 | -$13.96M 10-Q · filed 2020-05-15 |
| 2019-12-31 | -$11.53M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$13.69M 10-Q · filed 2019-11-14 |
| 2018-12-31 | -$8.76M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |